Citations

Clear

941 citation(s) found for "Tefferi, A".

The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance
Li, Marissa , Baranwal, Anmol , Gurney, Mark E. , Shah, Syed Nasir Ali, Al‐Kali, Aref , Foran, James M. , Yi, Cecilia Arana , Ongie, Laura , Mangaonkar, Abhishek A. , Tefferi, Ayalew , Lasho, Terra, Finke, Christy M. , Patnaik, Mrinal M. , Gurney, Mark , Shah, Syed N, Arana Yi, Cecilia , McCullough, Kristen B , Patnaik, Mrinal , Shah, Mithun V , Baranwal, Anmol , Li, Marissa M , Alkhateeb, Hassan B. , Chen, Dong , McCullough, Kristen , Lasho, Terra, Shah, Meera

Mayo Clinic

Blood Advances | April 2, 2024 | Volume: 8 | Issue: 12 | Pages: 3130-3139

10.1182/bloodadvances.2023012357 | PMID 38564774 Get It

Abstract Clonal cytopenia of undetermined significance (CCUS) is defined by a myeloid driver mutation in the context of otherwise unexplained cytopenia. CCUS has an inherent risk of progressing to myeloid neoplasm. However, it is unknown how exposure to previous cytotoxic therapy may impact the risk of progression and survival. We stratified patients with CCUS by prior exposure to DNA-damaging therapy. Of 151 patients, 46 (30%) had received cytotoxic therapy and were classified as therapy-related CCUS (t-CCUS), whereas 105 (70%) had de novo CCUS. A lower proportion of t-CCUS had hypercellular marrows (17.8% vs 44.8%, P = .002) but had higher median bone marrow blast percentages. After a median follow-up of 2.2 years, t-CCUS had significantly shorter progression-free survival (PFS, 1.8 vs 6.3 years; hazard ratio [HR], 2.1; P = .007) and median overall survival (OS; 3.6 years vs not reached; HR, 2.3; P = .007) compared with CCUS. Univariable and multivariable time-to-event analyses showed that exposure to cytotoxic therapy independently accounted for inferior PFS and OS. Despite the similarities in clinical presentation between CCUS and t-CCUS, we show that exposure to prior cytotoxic therapies was an independent risk factor for inferior outcomes. This suggests that t-CCUS represents a unique clinical entity that needs more stringent monitoring or earlier intervention strategies.
JAK inhibitor treatment‐resistant splenomegaly before transplantation in myelofibrosis: Splenectomy or radiotherapy?
Finazzi, Maria Chiara , Tefferi, Ayalew , Rambaldi, Alessandro , Rambaldi, Alessandro

Mayo Clinic

American Journal of Hematology | March 14, 2024 | Volume: 99 | Issue: 5 | Pages: 804-805

10.1002/ajh.27292 | PMID 38482991 Get It

Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management
Patnaik, Mrinal M. , Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | March 7, 2024 | Volume: 99 | Issue: 6 | Pages: 1142-1165

10.1002/ajh.27271 | PMID 38450850 Get It

AbstractDisease OverviewChronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, characterized by prominent monocytosis and an inherent risk for leukemic transformation (~15%–20% over 3–5 years).DiagnosisNewly revised diagnostic criteria include sustained (>3 months) peripheral blood (PB) monocytosis (≥0.5 × 109/L; monocytes ≥10% of leukocyte count), consistent bone marrow (BM) morphology, <20% BM or PB blasts (including promonocytes), and cytogenetic or molecular evidence of clonality. Cytogenetic abnormalities occur in ~30% of patients, while >95% harbor somatic mutations: TET2 (~60%), SRSF2 (~50%), ASXL1 (~40%), RAS pathway (~30%), and others. The presence of ASXL1 and DNMT3A mutations and absence of TET2 mutations negatively impact overall survival (ASXL1WT/TET2MT genotype being favorable).Risk StratificationSeveral risk models serve similar purposes in identifying high‐risk patients that are considered for allogeneic stem cell transplant (ASCT) earlier than later. Risk factors in the Mayo Molecular Model (MMM) include presence of truncating ASXL1 mutations, absolute monocyte count >10 × 109/L, hemoglobin <10 g/dL, platelet count <100 × 109/L, and the presence of circulating immature myeloid cells; the resulting 4‐tiered risk categorization includes high (≥3 risk factors), intermediate‐2 (2 risk factors), intermediate‐1 (1 risk factor), and low (no risk factors); the corresponding median survivals were 16, 31, 59, and 97 months. CMML is also classified as being “myeloproliferative (MP‐CMML)” or “myelodysplastic (MD‐CMML),” based on the presence or absence of leukocyte count of ≥13 × 109/L.TreatmentASCT is the only treatment modality that secures cure or long‐term survival and is appropriate for MMM high/intermediate‐2 risk disease. Drug therapy is currently not disease‐modifying and includes hydroxyurea and hypomethylating agents; a recent phase‐3 study (DACOTA) comparing hydroxyurea and decitabine, in high‐risk MP‐CMML, showed similar overall survival at 23.1 versus 18.4 months, respectively, despite response rates being higher for decitabine (56% vs. 31%).Unique Disease AssociationsThese include systemic inflammatory autoimmune diseases, leukemia cutis and lysozyme‐induced nephropathy; the latter requires close monitoring of renal function during leukocytosis and is a potential indication for cytoreductive therapy.
Risk models in myelofibrosis—the past, present, and future
Tefferi, Ayalew , Vannucchi, Alessandro M. , Vannucchi, Alessandro M

Mayo Clinic

American Journal of Hematology | February 24, 2024 | Volume: 99 | Issue: 4 | Pages: 519-522

10.1002/ajh.27270 | PMID 38400565 Get It

Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE‐A
Gangat, Naseema , Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | February 20, 2024 | Volume: 99 | Issue: 4 | Pages: 515-518

10.1002/ajh.27256 | PMID 38375926 Get It

New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors
Gangat, Naseema , Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | February 9, 2024 | Volume: 99 | Issue: 5 | Pages: 978-981

10.1002/ajh.27248 | PMID 38332640 Get It

Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents
Johnson, Isla McKerrow , Karrar, Omer , Rana, Masooma , Iftikhar, Moazah, Chen, Sunny , Saliba, Antoine N. , Al‐Kali, Aref , Begna, Kebede H. , Litzow, Mark R. , Patnaik, Mrinal M. , Pardanani, Animesh , Hermann, Joerg, Tefferi, Ayalew , Gangat, Naseema , Saliba, Antoine N. , Johnson, Isla M, Saliba, Antoine N , Al-Kali, Aref , Alkhateeb, Hassan B , Shah, Mithun V , Pardanani, Animesh , Tefferi, Ayalew , Gangat, Naseema , Saliba, Antoine N , McCullough, Kristen , Alkhateeb, Hassan B. , Hogan, William J. , Shah, Meera

Mayo Clinic

British Journal of Haematology | February 5, 2024 | Volume: 204 | Issue: 4 | Pages: 1232-1237

10.1111/bjh.19325 | PMID 38311378 Get It

SummaryAmong 301 newly diagnosed patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent, 23 (7.6%) experienced major cardiac complications: 15 cardiomyopathy, 5 non‐ST elevation myocardial infarction and/or 7 pericarditis/effusions. Four patients had more than one cardiac complication. Baseline characteristics included median age ± interquartile range; 73 ± 5 years; 87% males; 96% with cardiovascular risk factors; and 90% with preserved baseline ejection fraction. In multivariate analysis, males were more likely (p = 0.02) and DNMT3A‐mutated cases less likely (p < 0.01) to be affected. Treatment‐emergent cardiac events were associated with a trend towards lower composite remission rates (43% vs. 62%; p = 0.09) and shorter survival (median 7.7 vs. 13.2 months; p < 0.01). These observations were retrospectively retrieved and warrant further prospective examination.
Incidental discovery of KIT‐mutated mastocytoma in a colon polyp
Gangat, Naseema , Reichard, Kaaren K. , Orazi, Attilio , Pardanani, Animesh , Tefferi, Ayalew , McPhail, Ellen, Orazi, Attilio , Pardanani, Animesh , Tefferi, Ayalew , McPhail, Ellen Darcy

Mayo Clinic

American Journal of Hematology | January 25, 2024 | Volume: 99 | Issue: 5 | Pages: 973-974

10.1002/ajh.27209 | PMID 38270251 Get It

Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management
Tefferi, Ayalew , Vannucchi, Alessandro M. , Barbui, Tiziano , Vannucchi, Alessandro M

Mayo Clinic

American Journal of Hematology | January 25, 2024 | Volume: 99 | Issue: 4 | Pages: 697-718

10.1002/ajh.27216 | PMID 38269572 Get It

AbstractOverviewEssential thrombocythemia is a Janus kinase 2 (JAK2) mutation‐prevalent myeloproliferative neoplasm characterized by clonal thrombocytosis; clinical course is often indolent but might be interrupted by thrombotic or hemorrhagic complications, microcirculatory symptoms (e.g., headaches, lightheadedness, and acral paresthesias), and, less frequently, by disease transformation into myelofibrosis (MF) or acute myeloid leukemia.DiagnosisIn addition to thrombocytosis (platelets ≥450 × 109/L), formal diagnosis requires the exclusion of other myeloid neoplasms, including prefibrotic MF, polycythemia vera, chronic myeloid leukemia, and myelodysplastic syndromes with ring sideroblasts and thrombocytosis. Bone marrow morphology typically shows increased number of mature‐appearing megakaryocytes distributed in loose clusters.Genetics: Approximately 80% of patients express myeloproliferative neoplasm driver mutations (JAK2, CALR, MPL), in a mutually exclusive manner; in addition, about 50% harbor other mutations, the most frequent being TET2 (9%–11%), ASXL1 (7%–20%), DNMT3A (7%), and SF3B1 (5%). Abnormal karyotype is seen in <10% of patients and includes +9/20q−/13q‐.Survival and PrognosisLife expectancy is less than that of the control population. Median survival is approximately 18 years but exceeds >35 years in younger patients. The triple A survival risk model, based on Age, Absolute neutrophil count, and Absolute lymphocyte count, effectively delineates high‐, intermediate‐1‐, intermediate‐2‐, and low‐risk disease with corresponding median survivals of 8, 14, 21, and 47 years.Risk Factors for ThrombosisFour risk categories are considered: very low (age ≤60 years, no thrombosis history, JAK2 wild‐type), low (same as very low but JAK2 mutation present), intermediate (same as low but age >60 years), and high (thrombosis history or age >60 years with JAK2 mutation).Mutations and PrognosisMPL and CALR‐1 mutations have been associated with increased risk of MF transformation; spliceosome with inferior overall and MF‐free survival; TP53 with leukemic transformation, and JAK2V617F with thrombosis. Leukemic transformation rate at 10 years is <1% but might be higher in JAK2‐mutated patients with extreme thrombocytosis and those with abnormal karyotype.TreatmentThe main goal of therapy is to prevent thrombosis. In this regard, once‐daily low‐dose aspirin is advised for all patients and twice daily for low‐risk disease. Cytoreductive therapy is advised for high‐risk and optional for intermediate‐risk disease. First‐line cytoreductive drugs of choice are hydroxyurea and pegylated interferon‐α and second‐line busulfan.Additional ContentThe current review includes specific treatment strategies in the context of extreme thrombocytosis, pregnancy, splanchnic vein thrombosis, perioperative care, and post‐essential thrombocythemia MF, as well as new investigational drugs.
CALR mutation burden in essential thrombocythemia and disease outcome
Guglielmelli, Paola , Szuber, Natasha , Gangat, Naseema , Capecchi, Giulio , Maccari, Chiara , Harnois, Michaël, Karrar, Omer , Abdelmagid, Maymona, Balliu, Manjola , Nacca, Elena, Atanasio, Alessandro , Sestini, Ilaria, Désilets, Audrey , Loscocco, Giuseppe Gaetano , Rotunno, Giada, Busque, Lambert , Tefferi, Ayalew , Vannucchi, Alessandro M , Loscocco, Giuseppe Gaetano , Szuber, Natasha , Guglielmelli, Paola , Vannucchi, Alessandro M.

Mayo Clinic

Blood | January 22, 2024 | Volume: 143 | Issue: 13 | Pages: 1310-1314

10.1182/blood.2023023428 | PMID 38252902 Get It

Abstract Among 281 patients with essential thrombocythemia and calreticulin (CALR) mutation, we found a variant allele frequency of ≥60% to be associated with significantly shortened myelofibrosis-free survival, mostly apparent with CALR type-1 and CALR type-indeterminate mutations.